Kumar Jitendra, Alagarsamy Ragavi, Lal Babu, Rai Anshul J, Joshi Rajnish, Karna Sunaina Tejpal, Shakti Prateek, Verma Dinesh Kumar, Yadav Vineeta, Goel Pankaj, Yunus Md, Barathi Arivarasan
Department of Dentistry, All India Institute of Medical Sciences, Bhopal, India.
Department of Burns, Plastic and Maxillofacial Surgery, Vardhaman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
J Minim Invasive Surg. 2024 Dec 15;27(4):202-216. doi: 10.7602/jmis.2024.27.4.202.
Postoperative nausea and vomiting (PONV) is a prevalent and distressing complication, especially in laparoscopic surgeries. This review compares the efficacy and safety of palonosetron and ondansetron in preventing PONV after laparoscopic surgery.
A systematic review was conducted in PubMed, Google Scholar, Semantic Scholar, and Cochrane Library to identify comparative studies that reported the efficacy (nausea and vomiting) at three postoperative time points T1 (0-2 hours), T2 (2-6 hours), T3 (6-24 hours) and safety (incidence of adverse effects). Meta-analysis of relative risk was performed using a random effect model and subgroup analysis based on factors such as antiemetic dose and timing of administration, type of surgery, and anesthetic agents.
Twenty-one randomized controlled trials were published between 2011 and 2022, involving 2,043 participants. Nineteen trials were included in the meta-analysis (efficacy, 17; safety, 11). The pooled risk ratio revealed that patients receiving palonosetron demonstrated significantly less likelihood of developing nausea and vomiting at various postoperative time points. Subgroup analysis indicated significantly less PONV when palonosetron was administered before intubation and in combination with isoflurane anesthesia. Headache, dizziness, constipation, and drowsiness were the most commonly reported. The safety profiles of palonosetron and ondansetron were comparable.
Palonosetron exhibits superior efficacy within the first 24 hours postoperatively and requires less rescue antiemetic intervention compared to ondansetron in laparoscopic surgery patients. Both demonstrate nearly comparable safety profiles. Future trials focusing on cardiac safety (QT interval) and cost consideration are needed.
术后恶心呕吐(PONV)是一种常见且令人痛苦的并发症,尤其是在腹腔镜手术中。本综述比较了帕洛诺司琼和昂丹司琼在预防腹腔镜手术后PONV方面的疗效和安全性。
在PubMed、谷歌学术、语义学者和考克兰图书馆进行系统综述,以确定报告术后三个时间点T1(0 - 2小时)、T2(2 - 6小时)、T3(6 - 24小时)的疗效(恶心和呕吐)以及安全性(不良反应发生率)的比较研究。使用随机效应模型对相对风险进行荟萃分析,并根据止吐药剂量和给药时间、手术类型和麻醉剂等因素进行亚组分析。
2011年至2022年间发表了21项随机对照试验,涉及2043名参与者。19项试验纳入荟萃分析(疗效,17项;安全性,11项)。汇总风险比显示,接受帕洛诺司琼的患者在术后各个时间点发生恶心和呕吐的可能性显著降低。亚组分析表明,在插管前使用帕洛诺司琼并与异氟烷麻醉联合使用时,PONV显著减少。最常报告的不良反应为头痛、头晕、便秘和嗜睡。帕洛诺司琼和昂丹司琼的安全性相当。
在腹腔镜手术患者中,与昂丹司琼相比,帕洛诺司琼在术后24小时内表现出更高的疗效,且需要更少的补救性止吐干预。两者的安全性几乎相当。未来需要关注心脏安全性(QT间期)和成本考量的试验。